Knopp Biosciences LLC announced it received U.S. Patent No. 9,468,630 entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils”. The patent relates to the company’s clinical-stage small molecule dexpramipexole, which Knopp expects to advance into pivotal trials in HES and Phase 2 trials in eosinophilic asthma in 2017. Read more…
Comments are closed.